Clinical trial
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage…
NCT00459121 · Barbara Ann Karmanos Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00459121 |
|---|---|
| Title | Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery |
| Official title | Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | carboplatin, paclitaxel, Zactima, neoadjuvant therapy |
| Enrollment | 2 |
| Start date | Jul 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Apr 11, 2007 |
| Last update posted | Mar 26, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: